公开(公告)号：US12083159B2

公开(公告)日：2024-09-10

申请号：US16811754

申请日：2020-03-06

Applicant: MOREHOUSE SCHOOL OF MEDICINE

Inventor： Vincent Craig Bond ,  Michael Powell ,  Ming Bo Huang ,  Syed Ali ,  Martin N. Shelton

IPC: A61K38/16 ,  A61K38/08 ,  A61K45/06 ,  A61K47/60 ,  A61K47/64 ,  C07K7/06 ,  C07K14/005 ,  C12N7/00

CPC classification number: A61K38/162 ,  A61K38/08 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6455 ,  C07K7/06 ,  C07K14/005 ,  C12N7/00 ,  C07K2319/10 ,  C12N2740/16032 ,  C12N2740/16322 ,  Y02A50/30

Abstract: Compositions and methods for reducing the growth of and/or preventing the formation of a microbial biofilm are disclosed. The composition comprises an antimicrobial SMR peptide comprising an HIV-1 SMRwt peptide and a cell penetrating peptide (CPP) domain. In some embodiments, the composition further comprises one or more other antimicrobial peptides (AMPs), antibiotics, matrix-inhibiting compounds, matrix-disaggregating compounds, quorum sensing inhibitors, or a combination thereof. In other embodiments, the compositions are used for impregnating or coating an article and/or material surface with the composition to render it less prone to microbial infections.

公开(公告)号：US11976280B2

公开(公告)日：2024-05-07

申请号：US18063397

申请日：2022-12-08

Applicant: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD.

Inventor： Varda Shoshan-Barmatz ,  Yakov Krelin ,  Avijit Paul

IPC: C07K14/00 ,  A61K47/64 ,  A61P35/00 ,  C07K14/47 ,  C12N15/113

CPC classification number: C12N15/1135 ,  A61K47/64 ,  A61K47/6455 ,  A61P35/00 ,  C07K14/4747 ,  C12N2310/14 ,  C12N2310/321

Abstract: The present invention relates to compositions and methods for treating cancer, particularly to agents that inhibit the expression and/or activity of the protein second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (SMAC/Diablo). The inhibiting agents include RNA interference molecules silencing the expression of SMAC/Diablo and peptides modulating its interactions within the cell nucleus and mitochondria. The methods and agents of the present invention are useful in treating cancers associated with overexpression of SMAC/Diablo.

公开(公告)号：US11938191B2

公开(公告)日：2024-03-26

申请号：US16864613

申请日：2020-05-01

Applicant: Genevant Sciences GmbH

Inventor： Sean D. Monahan ,  Michael S. Declue ,  Pierrot Harvie ,  Russell N. Johnson ,  Amber E. Paschal ,  Mary G. Prieve ,  Debashish Roy ,  Charbel Diab ,  Michael E. Houston, Jr. ,  Anna Galperin ,  Maher Qabar

IPC: A61K47/64 ,  A01K67/027 ,  A61K38/08 ,  A61K38/44 ,  A61K47/54 ,  A61K47/58 ,  A61K48/00 ,  C08F293/00 ,  C12N15/113 ,  C12N15/87

CPC classification number: A61K47/6455 ,  A01K67/027 ,  A61K38/08 ,  A61K38/44 ,  A61K47/549 ,  A61K47/58 ,  A61K48/0041 ,  C08F293/005 ,  C12N15/113 ,  C12N15/87 ,  A01K2207/05 ,  C12N2310/14 ,  C12N2310/351 ,  C12N2320/32 ,  C12Y113/12007

Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.

公开(公告)号：US20240050582A1

公开(公告)日：2024-02-15

申请号：US18280316

申请日：2022-03-07

Applicant: UNIVERSITEIT GENT ,  ELICITYL

Inventor： Eric COX ,  Ut NGUYEN VAN ,  Benoit DARBLADE ,  Ludovic BASTIDE ,  Silvère BONNET

IPC: A61K47/64 ,  A61P31/04

CPC classification number: A61K47/6455 ,  A61P31/04

Abstract: Conjugates (I), useful for pig feeds, include saccharidic chains X(Fucα2)Galβk(Y)TV (II) covalently grafted on a linear protein W, wherein: X is absent, or is Galα3 or GalNAcα3 and when X is absent, then Y is absent; Y is absent or is Fucα2 or Fucα4; T is absent or is ZNAcε3; wherein Z is Glc or Gal; and ε is α or β; V is absent or is a mono, or an oligosaccharide; n is an integer equal to 8 or more, k is 3 or 4, and wherein the covalent grafting occurs either between V and the linear protein W, when V is present, or between T and the linear protein W, when T is present and V is absent, or between Galβk and the linear protein W, when both T and V are absent; and wherein the saccharidic unit covalently bonded to the linear protein may be open and acyclic.

公开(公告)号：US20240042048A1

公开(公告)日：2024-02-08

申请号：US18257594

申请日：2021-12-14

Applicant: SEASUN THERAPEUTICS

Inventor： Yu-Sun KANG ,  Hye Joo KIM ,  Ji-Yeon YU ,  Hee Kyung PARK

IPC: A61K47/64 ,  C07K7/08 ,  A61K47/22 ,  A61P35/00 ,  A61K31/7088

CPC classification number: A61K47/6455 ,  C07K7/08 ,  A61K47/22 ,  A61P35/00 ,  A61K31/7088

Abstract: The present invention relates to a pharmaceutical composition that is for treating pancreatic cancer and contains a nucleic acid complex as an active ingredient, and more specifically, to a pharmaceutical composition that is for preventing or treating pancreatic cancer and contains a nucleic acid complex in which a bioactive peptide nucleic acid, having a sequence binding to the KRAS gene, and a carrier peptide nucleic acid are complementarily bound. The nucleic acid complex according to the present invention has excellent cell permeability and intracellular activity, and can effectively inhibit the expression of the KRAS gene and subtype genes thereof, and is thus useful for the prevention or treatment of pancreatic cancer.

公开(公告)号：US20240026375A1

公开(公告)日：2024-01-25

申请号：US18458076

申请日：2023-08-29

Applicant: LIGANDAL, INC.

Inventor： Andre WATSON ,  Christian FOSTER

IPC: C12N15/85 ,  A61K47/68 ,  A61K48/00 ,  A61K47/54 ,  A61K31/7105 ,  A61K31/40 ,  A61K47/42 ,  B82Y5/00 ,  A61K47/64 ,  C12N15/87 ,  A61K9/00 ,  C12N15/11 ,  A61P37/00 ,  A61P3/10 ,  A61P35/00 ,  A61K9/51 ,  A61K47/34 ,  C12N15/10

CPC classification number: C12N15/85 ,  A61K47/6807 ,  A61K48/0016 ,  A61K47/549 ,  A61K31/7105 ,  A61K31/40 ,  A61K47/42 ,  B82Y5/00 ,  A61K47/64 ,  C12N15/87 ,  A61K9/0085 ,  A61K9/0019 ,  A61K47/6455 ,  C12N15/111 ,  A61K47/645 ,  A61P37/00 ,  A61P3/10 ,  A61P35/00 ,  A61K9/5146 ,  A61K47/34 ,  A61K48/0041 ,  A61K48/0075 ,  C12N15/102 ,  C12N2310/14 ,  C12N2310/3517 ,  C12N2320/32 ,  C12N2310/20 ,  C12N9/22

Abstract: Provided are methods and compositions for delivering a nucleic acid, protein, and/or ribonucleoprotein payload to a cell. Also provided are delivery molecules that include a peptide targeting ligand conjugated to a protein or nucleic acid payload (e.g., an siRNA molecule), or conjugated to a charged polymer polypeptide domain (e.g., poly-arginine such as 9R or a poly-histidine such as 6H, and the like). The targeting ligand provides for (i) targeted binding to a cell surface protein, and (ii) engagement of a long endosomal recycling pathway. As such, when the targeting ligand engages the intended cell surface protein, the delivery molecule enters the cell (e.g., via endocytosis) but is preferentially directed away from the lysosomal degradation pathway.

公开(公告)号：US20230346963A1

公开(公告)日：2023-11-02

申请号：US18246193

申请日：2021-09-24

Applicant: SEASUN THERAPEUTICS

Inventor： Min-Jung PARK ,  Hye Joo KIM ,  Ji-Yeon YU ,  Hee Kyung PARK

IPC: A61K47/64 ,  A61P25/28

CPC classification number: A61K47/6455 ,  A61K47/64 ,  A61P25/28

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating dementia, containing a nucleic acid complex in which a carrier peptide nucleic acid and a bioactive peptide nucleic acid having a sequence for binding to a NLRP3 gene are complementarily bound. The nucleic acid complex according to the present invention has a blood-brain barrier penetration ability and can effectively inhibit expression and phosphorylation of the protein of the NLRP3 gene and tau, which a lower-level gene, and thus is useful in the prevention or treatment of dementia.

公开(公告)号：US20230304014A1

公开(公告)日：2023-09-28

申请号：US18003982

申请日：2021-07-01

Applicant: Biorchestra Co., Ltd.

Inventor： Jin-Hyeob RYU ,  Han Seok KOH ,  Dae Hoon KIM ,  Hyun Su MIN ,  Yu Na LIM

IPC: C12N15/113 ,  A61K47/60 ,  A61K47/64 ,  A61K47/54 ,  A61P25/28

CPC classification number: C12N15/1137 ,  A61K47/545 ,  A61K47/60 ,  A61K47/6455 ,  A61P25/28 ,  C12N2310/14 ,  C12N2310/313

Abstract: The present disclosure includes the use of a miRNA inhibitor for treating a symptom or condition of Huntington’s disease. The miRNA inhibitor useful for the present disclosure can inhibit miR-485 expression and/or activity, which in turn can modulate the level of proteins or gene expression related to Huntington’s disease.

公开(公告)号：US11744886B2

公开(公告)日：2023-09-05

申请号：US16838746

申请日：2020-04-02

Applicant: CureVac Manufacturing GmbH

Inventor： Thorsten Mutzke ,  Markus Kreuz ,  Stefanie Sewing ,  Fabian Johannes Eber ,  Wenke Wagner ,  Michael Sonntag ,  Michael Wiggenhorn ,  Katharina Kolland

IPC: A61K39/145 ,  A61K48/00 ,  A61K47/64 ,  A61K9/51 ,  A61K39/12 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K9/5169 ,  A61K9/5192 ,  A61K39/12 ,  A61K47/646 ,  A61K47/6455 ,  A61K2039/55555 ,  C12N2760/16134

Abstract: The present invention relates to a method for producing a liquid composition comprising a nanoparticle comprising at least one RNA and at least one cationic or polycationic compound, advantageously on a large scale suitable for pharmaceutical applications. The present invention further concerns the use of the inventive method in the manufacture of a medicament or a vaccine. Furthermore, the invention relates to compositions containing the RNA-comprising nanoparticle, and to pharmaceutical compositions comprising the same.

公开(公告)号：US11723967B2

公开(公告)日：2023-08-15

申请号：US15999469

申请日：2017-02-17

Applicant: CureVac SE ,  Sanofi Pasteur

Inventor： Benjamin Petsch ,  Edith Jasny ,  Yves Girerd-Chambaz

IPC: A61K39/12 ,  A61K47/64 ,  A61P31/14 ,  A61K39/385 ,  C07K14/005

CPC classification number: A61K39/12 ,  A61K39/385 ,  A61K47/646 ,  A61K47/6455 ,  A61P31/14 ,  C07K14/005

Abstract: The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.